Bristol-Myers Squibb resubmits hepatitis C drug for review

Pharmaceutical Company Product News

Bristol-Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has agreed to review a new drug it has developed for the treatment of hepatitis C.

The pharmaceutical firm had a previous application for the treatment rejected, but the FDA has now accepted daclatasvir for review.

“Bristol-Myers Squibb has resubmitted an application for the development of a new hepatitis C drug, which is now under review by the US Food and Drug Administration.“

Daclatasvir is designed to lessen the symptoms og chronic hepatitis C, with a recent phase III trial revealing that it has a success rate of around 90 per cent after 12 weeks of use.

As this trial was conducted over a short period of time, the FDA will now carry out its own tests on the drug to assess the potential effectiveness of taking it over six months.

Explaining what's next for BMS, its head of specialty development Douglas Manion said: "We also are continuing clinical trials to determine the potential of daclatasvir-based regimens in treating a range of other high unmet-need patients, including those coinfected with HIV."

Statistics show that around 170 million people are currently infected with hepatitis C worldwide.

See all the latest jobs in Pharmaceutical
Return to news